Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07055568

A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
18 (estimated)
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To evaluate the preliminary safety and tolerability of iNKT cell injection after infusion in each group of subjects, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for extended studies.

Conditions

Interventions

TypeNameDescription
DRUGiNKTiNKT: Intravenous infusion, 0.5×10\^8cell-3.0×10\^8 cell

Timeline

Start date
2025-09-30
Primary completion
2027-09-30
Completion
2028-01-30
First posted
2025-07-09
Last updated
2025-07-09

Source: ClinicalTrials.gov record NCT07055568. Inclusion in this directory is not an endorsement.

A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subje (NCT07055568) · Clinical Trials Directory